Latest:
Dr Alawadhi on the Link Between Obesity/Overweight and Breast Cancer Outcomes
Aydah Alawadhi, MBBS, discusses the effect of obesity and overweight status on patient outcomes across subgroups of early-stage breast cancer.
Authors
Elizabeth Wulff-Burchfield, MD
Latest:
Post-Immunotherapy Options in RCC: Latest Trial Data and Expert Perspectives on Rechallenge Strategies
Experts discuss key findings from the phase 3 CONTACT-03 trial investigating atezolizumab plus cabozantinib vs cabozantinib alone in inoperable advanced renal cell carcinoma (aRCC) after immune checkpoint inhibitor (ICI) treatment, along with insights from real-world data on sequencing strategies and the efficacy of tyrosine kinase inhibitors (TKIs) after prior ICI therapy.
Hyein Jeon, MD
Hyein Jeon, MD, is a hematology oncology fellow at Albert Einstein College of Medicine and Montefiore Medical Center
Latest:
Dr Jeon on Research Presented at an OncLive Lung Cancer Fellows Forum
Hyein Jeon, MD, highlights key abstracts and takeaways from an OncLive Fellows Forum on lung cancer.
Julie E. Chang, MD
Latest:
COVID-19 Pandemic Highlights Underrecognized Vulnerability of Patients With CLL
At the onset of the pandemic, hematology/oncology physicians were challenged in counseling patients with serious underlying malignant conditions about their risk for severe disease due to COVID-19.
Joshua F. Zeidner, MD
University of North Carolina, Lineberger Comprehensive Cancer Center
Latest:
Phase 1b Study of Azacitidine, Venetoclax and Revumenib in Newly Diagnosed Older Adults with NPM1 Mutated or KMT2A Rearranged AML: Interim Results of Dose Escalation from the Beat AML Consortium
A Phase 1b study (NCT03013998) to determine the safety and recommended dose of Revumenib combined with Aza/Ven in patients with newly diagnosed AML ≥ 60 years old with NPM1mut or KMT2Ar and who are not candidates or do not wish to pursue intensive induction therapy.
Neal Navani, MRCP, MSc, PhD, University College London Hospitals NHS Foundation Trust
Latest:
EGFR+ NSCLC: Advice for Community Oncologists
A panel of experts in thoracic oncology concludes the discussion by emphasizing the importance of conducting reflex molecular testing, considering systemic therapy in all patients, and utilizing shared decision-making models.
Enrique Grande, MD, PhD, Msc
Latest:
Cabozantinib plus Atezolizumab in Locally Advanced/Metastatic Adrenocortical Carcinoma: Results From a Multi-Cohort Basket Phase II Trial (CABATEN/GETNE-T1914)
Enrique Grande, MD, PhD, Msc, presents the results of a multi-cohort basket phase II trial, CABATEN/GETNE-T1914, evaluating cabozantinib plus atezolizumab in patients with locally advanced/metastatic adrenocortical carcinoma.